Endometrial Cancer Recurrence in Patients Taking Metformin
Withdrawn before enrolling
Conditions studied: Recurrent Endometrial Carcinoma
In brief
Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take metformin for non-cancer related reasons have a lower cancer recurrence rate compared to women not taking metformin. The primary goal of this study is to determine whether metformin use is associated with a decrease in the rate of endometrial cancer recurrence. Secondary objectives are to assess whether women with endometrial cancer taking metformin have longer progression free survival and overall survival than those that do not take metformin.
Key facts
- Study ID
- NCT05192850
- Run by
- WellSpan Health
- People needed
- 0
- Starts
- 2021-12-27
- Expected to finish
- 2023-02-27
- Last updated by the study team
- 2025-03-28
Who can join
Age: 18 and older, up to 99. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Participants with endometrial cancer of all histologies treated in the WellSpan system from 2016-2020
You may not qualify if…
- Participants who underwent palliative treatment for endometrial cancer
Where it is running
- WellSpan — York, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.